TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

NCT06323525 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non-hodgkin Lymphoma

Interventions

BIOLOGICAL: TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T)
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Chinese PLA General Hospital